Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK-Reference-Cited by-同舟云学术

Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK

Published:2018-04-24 Issue:3 Volume:8 Page:211-225
ISSN:1758-8103
Container-title:Clinical Obesity
language:en
Short-container-title:Clin Obes

Author:

Wilding J. P. H.¹^ORCID

Affiliation:

1. Obesity and Endocrinology Clinical Research; University of Liverpool & Aintree University Hospital; Liverpool UK

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cob.12248/fullpdf

Reference77 articles.

1. OECD 2017 http://www.oecd.org/els/health-systems/Obesity-Update-2017.pdf

2. National Institute for Health and Care Excellence (NICE) 2014 https://www.nice.org.uk/guidance/cg189/resources/obesity-identification-assessment-and-management-pdf-35109821097925

3. National Institute for Health and Care Excellence (NICE) 2014 https://www.nice.org.uk/guidance/ph53/resources/weight-management-lifestyle-services-for-overweight-or-obese-adults-1996416726469

4. Scottish Intercollegiate Guidelines Network (SIGN) 2010 http://www.sign.ac.uk/assets/sign115.pdf

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real‐world UK data: A clinical evaluation of a multi‐ethnic population;Clinical Obesity;2024-03-04

2. Do People Reduce Attempts At Lifestyle Change After Initiating Weight Loss Medication? A Review Of Trial Evidence;2024-01-13

3. Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting;Family Practice;2022-12-08

4. Supporting patients living with obesity in general practice;Practice Nursing;2022-12-02

5. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy;International Immunopharmacology;2021-07